Lindsay A Md Rosenwald
CIK 941841 · PRESIDENT, CEO & CHAIRMAN · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FBIOP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DERM | Director | 397,616 | $4.98 | $1.98M | $321.4K | 8 | 2026-06-26 |
| FBIOP | PRESIDENT, CEO & CHAIRMAN | 4,586,841 | $16.10 | $73.85M | $7.68M | 24 | 2026-03-20 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 157,007 | $4.26 | $668.8K | $356.2K | 12 | 2025-05-30 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 4,724 | $0.35 | $1.7K | $543.7K | 7 | 2024-09-25 |
| MBIO | Director | 1,210 | $0.36 | $436 | $758.1K | 12 | 2023-07-07 |
| FBIO | PRESIDENT, CEO | 8,000 | $1.90 | $15.2K | $1.01M | 6 | 2017-11-08 |
| Origo Acquisition Corp (CNLM.W) Delisted | Co-Chairman and CEO | 265,000 | — | — | $0 | 2 | 2016-05-23 |
| Fortress Biotech, Inc. (CNDO) Delisted | President and CEO | 4,962,304 | — | — | $1.36M | 16 | 2014-12-03 |
| NVD | 10%+ Owner | 85,506 | $3.96 | $339.0K | $0 | 1 | 2007-01-23 |
Recent Filings · Page 5 of 11
102 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-09 | FBIOP | Grant (A) | +1,033,191 | $5.6K | EDGAR |
| 2021-03-15 | MBIO | Grant (A) | +1,043 | $3.0K | EDGAR |
| 2020-12-22 | MBIO | Grant (A) | +17,442 | $43.3K | EDGAR |
| 2020-12-22 | MBIO | Mixed | +101,182 | $268.9K | EDGAR |
| 2020-12-15 | MBIO | Buy (P) | +100,000 | $266.0K | EDGAR |
| 2020-09-01 | FBIOP | Buy (P) | +52,500 | $945.0K | EDGAR |
| 2020-08-19 | MBIO | Grant (A) | +16,611 | $0 | EDGAR |
| 2020-06-09 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +24,390 | $0 | EDGAR |
| 2020-03-13 | FBIOP | Mixed | +804,126 | $3.9K | EDGAR |
| 2020-01-17 | MBIO | Grant (A) | +10,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.